TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

SANOFI-AVENTIS US

MetabolicOncologyRespiratory
Biotech

SANOFI-AVENTIS US is a biotechnology company focused on Metabolic, Oncology, Respiratory. Key products include ADLYXIN.

2016
Since
4
Drugs
-
Trials
4
Approved (2yr)

Key Drugs

SOLIQUA 100/33
insulin glargine
Metabolic
GLP-1R 2 indications · 2016
ADLYXIN
lixisenatide
Metabolic
GLP-1R 2 indications · 2016
ADMELOG
insulin lispro
Metabolic
1 indications · 2017
ADMELOG SOLOSTAR
insulin lispro
Metabolic
1 indications · 2017

Recent Activity

SOLIQUA 100/33 2025-05-28
Labeling
ADLYXIN 2025-05-28
Labeling
SOLIQUA 100/33 2024-11-01
Labeling
ADLYXIN 2024-11-01
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 37%
4 drugs Phase 3: 26 Phase 2: 7 Phase 1: 50
Oncology 21%
0 drugs Phase 3: 8 Phase 2: 21 Phase 1: 34
Respiratory 17%
0 drugs Phase 3: 14 Phase 2: 11 Phase 1: 8
Immunology 13%
0 drugs Phase 3: 7 Phase 2: 16 Phase 1: 9
Neurology 12%
0 drugs Phase 3: 11 Phase 2: 5 Phase 1: 8

Pipeline Strength Pro

Loading...

Competitors Pro

GSK big-pharma
Respiratory, Oncology, Immunology, Neurology
Sanofi big-pharma
Metabolic, Oncology, Immunology, Respiratory
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Roche big-pharma
Oncology, Neurology, Immunology, Respiratory
AstraZeneca big-pharma
Oncology, Respiratory, Metabolic, Immunology